(Original title: Watson is over 90% accurate in cancer treatment. Does the doctor feel happy or sad?) Watson, who became famous in the American Q&A program Jeopardy, has become more and more adept at developing cancer treatment programs. The data disclosed by the American Society of Clinical Oncology at its annual meeting last week showed that IBM's Watson's cancer treatment program most closely matched the doctor's recommendations. IBM also announced that its cancer care products to help doctors diagnose and treat patients have been put into use in nine new medical centers worldwide. In part of the research report submitted to ASCO, the researchers stated that Watson has now performed very well when it comes to recommending treatment options for different cancers. A study conducted in India showed that Watson's treatment recommendations were consistent with the doctor's protocol in the treatment of lung cancer in 96% of cases; the rate of compliance with doctor's recommendations was also high when treating rectal cancer and colon cancer. 93% and 81%. In addition, in a study conducted in Thailand, Watson gave similar treatment recommendations for colorectal cancer, lung cancer, breast cancer, and gastric cancer. Moreover, Watson screened breast cancer and lung cancer patients 78% faster than humans in clinical trials, reducing screening time from 110 minutes to 24 minutes. Watson is a cognitive computing system trained by doctors at Memorial Sloan-Kettering. It can extract relevant health information from the patient's medical history and provide a personalized treatment plan. Watson also knows which treatment options should not be taken and can provide a theoretical basis. All in all, it can use the latest research results to help doctors deal with different patients' conditions. Watson's success in healthcare is nothing new. However, these research results make it more effective and reliable for doctors. Watson has been used worldwide, and now it has added nine new hospitals to its customers, including medical institutions in Australia, Mexico and Southeast Asia. The MD Anderson Cancer Center at the University of Texas originally planned to introduce Watson, but the financial issue was temporarily shelved. According to IBM, Watson can now diagnose and evaluate prostate cancer. Andrew Norden, Deputy Chief Health Officer, IBM Watson Oncology and Genomics, said: "These studies show that Watson is working the way we want to help doctors improve their experience and expertise in evidence-based care." 燑br>